n/a (MBX)

: MBX · 实时价格 · USD

n/a

n/a (n/a)

收盘价： Invalid Date

暂无数据

买价	n/a
市值	n/a
营收（TTM）	n/a
净利润（TTM）	n/a
贝塔值	n/a
每股收益（TTM）	n/a
市盈率（TTM）	n/a
预期市盈率	n/a
市净率（TTM）	n/a
市销率（TTM）	n/a
Earnings Date	Nov 5, 2026

卖价	n/a
成交量	NaN
20日均量	n/a
开盘价	n/a
前收盘价	n/a
日内区间	n/a - n/a
52周区间	n/a - n/a
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 MBX

A detailed description of the company is not yet available....

[阅读更多]

行业 n/a

板块 n/a

上市日期 n/a

员工人数 n/a

交易所 n/a

股票代码 MBX

公司完整简介

财报意外

已于 Aug 6, 2026 发布季度财报：

营收为 $0 低于预期 $0, ， NaN% 同比增长.

每股收益为 -0.78 低于预期 -0.19, ， -34.48% 同比下滑.

下次财报发布时间

计划于以下时间发布财报 Nov 5, 2026, 开盘前。
分析师预计营收为 ... 升级

新闻

4天前 · Barrons.com

UMH Properties and 4 More Stocks See Action From Activist Investors

Activists also report to the SEC on MBX Biosciences, Core Scientific, Gran Tierra Energy, and Shoulder Innovations.

2周前 · Investor's Business Daily

Stock Market Checklist Helps Uncover Winners In Hot Biotechs

Use the IBD Stock Checklist to separate the wheat from the chaff in the stock market, specifically in the red-hot biotech sector.

2月前 · Simply Wall St.

How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?

MBX Biosciences recently reported full 12-week Phase 2 Avail trial results and one-year open-label extension data for once-weekly canvuparatide in adults with chronic hypoparathyroidism, showing highe...

2月前 · InvestorsHub

MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)

MBX Biosciences Inc. (NASDAQ:MBX) shares dropped 19.

2月前 · BioPharma Dive

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.

第 1 页，共 2 页